10-Q quarterly report · filed Nov 5, 2026

Organogenesis Holdings Inc. (ORGO) Q3 2026 10-Q Quarterly Report

Short answer

Organogenesis Holdings Inc. (ORGO) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $45M (down 69.9% year over year) with net income of −$30M.

Q3 2026 key financials · XBRL

Revenue
$45M
−69.9% YoY · +3.9% QoQ
Net income
−$30M
−237.4% YoY · +69.2% QoQ
Operating margin
-64.9%
EPS (diluted)
−$0.26
−273.3% YoY · +66.2% QoQ

Source: XBRL data from the Organogenesis Holdings Inc. (ORGO) Q3 2026 10-Q on SEC EDGAR. USD.

Organogenesis Holdings Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $45.5M, down 70% YoY from $150.9M, driven by Advanced Wound Care disruption
  • Gross margin 51.8% vs 75.8% YoY, reflecting Medicare reimbursement changes and product mix
  • Advanced Wound Care revenue $38.2M, down 73%; Surgical & Sports Medicine $7.3M, down 19%
  • Cash $21.3M at September 30; operating cash use $29.1M through nine months
  • Management expects significant YoY revenue declines in fourth quarter amid reimbursement headwinds and clinician confusion

Risk Factors

  • New capital-raising risk: declining cash, reduced product revenue, and Revolving Facility expiration on August 6, 2026
  • Liquidity risk: $75.0 million ATM capacity may remain inaccessible because it is not committed financing
  • Market risk: revenue disruption followed LCD coverage-policy withdrawal and CMS discarded-product comments
  • Shareholder dilution risk: future equity or convertible-debt financing could dilute existing stockholders

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Organogenesis Holdings Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.